--- title: FidoCure blog | Dr. Gerry Post description: Read the latest in veterinary oncology research and FidoCure® scientific and clinical updates. --- [![FidoCure](https://blog.fidocure.com/hs-fs/hubfs/fidocure_logo.png?width=296&height=68&name=fidocure_logo.png "FidoCure")](https://www.fidocure.com/) - [Veterinarians](https://fidocure.com/for-veterinarians/) - [Portal Login](https://dvm.fidocure.com/) - [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet) - [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies) - [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars) - [Pet Parents](https://fidocure.com/pet-parents/) - [About Us](https://fidocure.com/about-us/) - [How it works](https://fidocure.com/how-it-works/) - [Find a Clinic](https://fidocure.com/find-a-clinic/) - [Contact Us](https://fidocure.com/contact-us/) # FidoCure Veterinary Team Blog ### Read the latest in veterinary oncology research and FidoCure scientific and clinical updates from our team of experts and advisors Select Category Case Studies Press Vet Webinars This is a search field with an auto-suggest feature attached. - There are no suggestions because the search field is empty. Posts by: ## Dr. Gerry Post ![](https://blog.fidocure.com/hubfs/NErhart.png) ### [Great Danes to Grandads: Comparative Cancer and Aging Research](https://blog.fidocure.com/fidocure-blog/great-danes-to-grandads-comparative-cancer-and-aging-research) Dr. Ehrhart shares insight from her current work in comparative aging research and highlights its intersection with cancer and musculoskeletal research in veterinary medicine. [Read More](https://blog.fidocure.com/fidocure-blog/great-danes-to-grandads-comparative-cancer-and-aging-research) ![](https://blog.fidocure.com/hubfs/sZhao.png) ### [What Every Veterinary Oncologist Needs to Know About Cancer Genomics](https://blog.fidocure.com/fidocure-blog/what-every-veterinary-oncologist-needs-to-know-about-cancer-genomics) Genomics is fast becoming an essential part of veterinary oncology. It touches upon all aspects of practice, from diagnostics to therapeutics. Genetic information can be incredibly useful in terms of making a more accurate diagnosis or making a more precise prognosis, or even determining what therapy to use or what order to use different therapies. [Read More](https://blog.fidocure.com/fidocure-blog/what-every-veterinary-oncologist-needs-to-know-about-cancer-genomics) ![](https://blog.fidocure.com/hubfs/NMauldin.png) ### [The Path Ahead for Combination Therapy Approaches to Canine Cancer Treatment](https://blog.fidocure.com/fidocure-blog/the-path-ahead-for-combination-therapy-approaches-to-canine-cancer-treatment) We welcomed **Dr. Neal Mauldin, Chief Medical Officer, PetCure Oncology **to our webinar series. He is one of the **only triple-boarded veterinarians**, certified in the field of internal medicine, medical oncology and radiation oncology. [Read More](https://blog.fidocure.com/fidocure-blog/the-path-ahead-for-combination-therapy-approaches-to-canine-cancer-treatment) ![](https://blog.fidocure.com/hubfs/oliver-1-1.jpg) ### [TCC Case Study: Sir Oliver](https://blog.fidocure.com/fidocure-blog/tcc-case-study-sir-oliver) #### Sir Oliver, an 8 year old French Bulldog with TCC, is surviving and thriving thanks to his targeted therapeutic treatment4.5 months from FidoCure™ enrollment, Sir Oliver's latest CT scan showed a 38% reduction in his bladder tumor. [Read More](https://blog.fidocure.com/fidocure-blog/tcc-case-study-sir-oliver) ![](https://blog.fidocure.com/hubfs/missy.png) ### [Mammary Carcinoma Case Study: Missy](https://blog.fidocure.com/fidocure-blog/mammary-carcinoma-case-study-missy) #### After one year of FidoCure®targeted therapy, Missy showed no evidence of pulmonary metastatic disease.   [Read More](https://blog.fidocure.com/fidocure-blog/mammary-carcinoma-case-study-missy) ![](https://blog.fidocure.com/hubfs/duchess.png) ### [Squamous Cell Carcinoma Case Study: Duchess](https://blog.fidocure.com/fidocure-blog/squamous-cell-carcinoma-case-study-duchess) #### It is clear that the utilization of targeted therapy has proven beneficial in improving patient quality of life, extending survival time with minimal disease progression, and having an overall positive impact on patient care. [Read More](https://blog.fidocure.com/fidocure-blog/squamous-cell-carcinoma-case-study-duchess) ![](https://blog.fidocure.com/hubfs/Adley.jpg) ### [Lung Carcinoma Case Study: Adley Hurwitz](https://blog.fidocure.com/fidocure-blog/lung-carcinoma-case-study-adley-hurwitz) #### After six months of FidoCure® enabled therapy, Adley showed no evidence of pulmonary mass recurrence.   [Read More](https://blog.fidocure.com/fidocure-blog/lung-carcinoma-case-study-adley-hurwitz) ![](https://blog.fidocure.com/hubfs/forrest.jpg) ### [Hemophagocytic Histiocytic Sarcoma Case Study: Forrest](https://blog.fidocure.com/fidocure-blog/hemophagocytic-histiocytic-sarcoma-case-study-forrest) #### A 11 yr old Golden with hemophagocytic histiocytic sarcoma, 38 months in remission. FidoCure® identified a rare tumor suppressor mutation and suggested additional therapy that may have helped target tumor cells. [Read More](https://blog.fidocure.com/fidocure-blog/hemophagocytic-histiocytic-sarcoma-case-study-forrest) ![](https://blog.fidocure.com/hubfs/lulu.jpg) ### [Thyroid Carcinoma Case Study: Lulu](https://blog.fidocure.com/fidocure-blog/thyroid-carcinoma-case-study-lulu) #### After more than 20 months of FidoCure® enabled treatment, Lulu has remained free from further metaseses. There has been no evidence of disease recurrence or pulmonary metastasis. Lulu has maintained a positive quality of life while in treatment and achieved extended time with her pet owners. [Read More](https://blog.fidocure.com/fidocure-blog/thyroid-carcinoma-case-study-lulu) ![](https://blog.fidocure.com/hubfs/Imported_Blog_Media/shutterstock_1933410728.jpg) ### [World Veterinary Day Interview: Strengthening Veterinary Resilience](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/world-veterinary-day/amp) Resilience is defined as the capacity to recover quickly from difficulties and toughness-- there are both physical and psychological resilience. Both have been severely tested these last few years with the pandemic, the current war, national divisions, etc. and have really affected veterinarians in the world at large. [Read More](https://blog.fidocure.com/fidocure-blog/veterinary-oncology/blog/world-veterinary-day/amp) [1](https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post) [2](https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post/page/2) [3](https://blog.fidocure.com/fidocure-blog/author/dr-gerry-post/page/3) ![fc_portal_logo_bw](https://blog.fidocure.com/hubfs/fc_portal_logo_bw.svg) - [How it Works](https://fidocure.com/how-it-works/) - [FAQ](https://fidocure.com/faq/) - [Contact Us](https://fidocurestg.wpengine.com/contact-us/) - [For Vets](https://fidocure.com/for-veterinarians/) - [About Us](https://fidocure.com/about-us/) - [Terms of Service](https://fidocure.com/terms-of-service/) - [Blog](https://blog.fidocure.com/fidocure-blog) - [Careers](https://fidocure.com/careers/) - [Privacy Policy](https://fidocure.com/privacy-policy/) - - - - **FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.  © Copyright 2018-2026 One Health Company, All rights reserved